1stOncology™: Cancer Intelligence Service – Page 7345 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference

On February 9, 2022 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, reported that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare conference taking place on Wednesday, February 16, 2022, at 8:40 a.m. Eastern Time (Press release, Aura Biosciences, FEB 9, 2022, View Source [SID1234607925]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company’s website at View Source, where a replay of the webcast will be archived for 90 days following the presentation date.

Elpiscience Announces CDE Clearance of IND Application for Anti-CD39 Monoclonal Antibody ES002

On February 9, 2022 Elpiscience Biopharmaceuticals, Inc. ("Elpiscience"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, reported that the Center of Drug Evaluation (CDE) has cleared Elpiscience’s Investigational New Drug Application (IND) for ES002 to initiate a Phase I clinical trial in China (Press release, Elpiscience, FEB 9, 2022, View Source [SID1234607924]).

ES002 is a proprietary anti-CD39 monoclonal antibody (mAb), which has demonstrated highly potent single-agent anti-tumor activity showing a significant reduction in tumor size in in vivo pharmacology studies.

"We are delighted that our IND application for ES002 is approved by the CDE, which follows the earlier IND and Phase I clinical study initiation in the US," said Dr. Steve Chin, CMO of Elpiscience. "Robust preclinical data suggests that our anti-CD39 mAb has a potential best-in-class profile, including a strong effect on T cell function and superior enzymatic inhibition. We look forward to initiating the study in China and potential clinical benefits ES002 may offer for patients with solid tumors worldwide."

About ES002:

ES002 is an anti-CD39 mAb designed to promote anti-tumor immunity. CD39 is a key enzyme regulating the production of adenosine, a critical immune suppressor. By blocking CD39 function, ES002 also stabilizes pro-inflammatory extracellular ATP (eATP) and restores anti-tumor immunity within the tumor microenvironment. ES002 demonstrated highly potent single-agent anti-tumor activity in in-vivo pharmacology studies and is currently in a Phase 1 clinical trial in the US (NCT05075564).

Quanterix to Participate in the SVB Leerink Global Healthcare Conference

On February 9, 2022 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, reported that its Chairman and Chief Executive Officer, Kevin Hrusovsky, will present virtually at the SVB Leerink Global Healthcare Conference on Feb. 16 at 4:20 p.m., EST (Press release, Quanterix, FEB 9, 2022, View Source [SID1234607923]). To register for the live webcast, please visit View Source;page=qtrx&url=View Source

A live webcast of the presentation will be available on the investor section of the Quanterix website at View Source Replays of the webcast will be available on the Quanterix website for 90 days following the conference. Hrusovsky will also host virtual one-on-one meetings with institutional investors on Feb. 18.

EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immune Cell Therapies

On February 9, 2022 EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, and Neukio Biotherapeutics, a biotechnology company focused on the development and commercialization of allogenic iPSC-CAR-NK cell therapies, reported an R&D collaboration to develop next-generation immune cell therapies (Press release, EdiGene, FEB 9, 2022, View Source [SID1234607922]).

The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell).

"Our proprietary, high-throughput genome-editing screening platform enables genome-wide exploration of key genes in the growth and differentiation of specific cells, promotes the establishment of causality between genetic variation and therapeutic development, and has unique advantages in mechanism exploration, target screening and translation," said Dong Wei, Ph.D., CEO of EdiGene. "By leveraging our expertise in the application and translation of gene editing technologies, we are able to facilitate the development of innovative iPSC-NK immune cell therapies to bring more treatment options to patients."

"The first autologous CAR-T cell therapy was launched in China in 2021, providing hope to cancer patients that they will be able to benefit from the next generation of cell therapies as soon as possible. Our collaboration with EdiGene will explore new therapeutic mechanisms and targets, so that our NK cells can be used for allogenic therapies to treat solid tumors, which is beneficial for our intellectual properties systems and for patients’ accessibility," said Dr. Richard Wang, Founder, Chairman and CEO of Neukio. "This new screening method supplements known targets, laying a solid foundation for Neukio’s pipeline and sustainable development."

Under the agreement, Neukio will develop cell therapies in certain undisclosed indications and pay EdiGene milestone payments for clinical development upon its clinical progress, and royalties after its commercialization.

Biodesix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

On February 9, 2022 Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, reported Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held virtually February 15-17, 2022 (Press release, Biodesix, FEB 9, 2022, View Source [SID1234607921]).

BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Date: Wednesday, February 16, 2022
Time: 4:30 PM ET